- Home
- NPV vs CVRX Comparison
NPV vs CVRX Comparison
Compare NPV & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- CVRX
- Stock Information
- Founded
- NPV 1993
- CVRX 2000
- Country
- NPV United States
- CVRX United States
- Employees
- NPV N/A
- CVRX N/A
- Industry
- NPV Investment Managers
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NPV Finance
- CVRX Health Care
- Exchange
- NPV Nasdaq
- CVRX Nasdaq
- Market Cap
- NPV 199.1M
- CVRX 203.9M
- IPO Year
- NPV N/A
- CVRX 2021
- Fundamental
- Price
- NPV $11.46
- CVRX $7.95
- Analyst Decision
- NPV
- CVRX Buy
- Analyst Count
- NPV 0
- CVRX 7
- Target Price
- NPV N/A
- CVRX $14.00
- AVG Volume (30 Days)
- NPV 38.9K
- CVRX 194.9K
- Earning Date
- NPV 01-01-0001
- CVRX 10-28-2025
- Dividend Yield
- NPV 3.90%
- CVRX N/A
- EPS Growth
- NPV N/A
- CVRX N/A
- EPS
- NPV N/A
- CVRX N/A
- Revenue
- NPV N/A
- CVRX $54,652,000.00
- Revenue This Year
- NPV N/A
- CVRX $11.32
- Revenue Next Year
- NPV N/A
- CVRX $18.58
- P/E Ratio
- NPV N/A
- CVRX N/A
- Revenue Growth
- NPV N/A
- CVRX 23.11
- 52 Week Low
- NPV $8.92
- CVRX $4.30
- 52 Week High
- NPV $11.55
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- NPV 74.17
- CVRX 57.30
- Support Level
- NPV $11.25
- CVRX $7.22
- Resistance Level
- NPV $11.37
- CVRX $7.96
- Average True Range (ATR)
- NPV 0.08
- CVRX 0.42
- MACD
- NPV 0.03
- CVRX 0.04
- Stochastic Oscillator
- NPV 98.91
- CVRX 90.82
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.